CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy

VANCOUVER, Washington, Jan. 11, 2017, CYDY, (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced the Company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure. While the standard of care for HIV infection has been a combination of medications from different antiretroviral classes that interfere with different
http://bit.ly/2jiXXGj